Press Release

Cell & Gene Therapy Cold Chain Logistics Market to Grow at 14.11% CAGR through 2029

Expansion of healthcare infrastructure and increasing regulatory approvals of cell and gene therapies is expected to drive the Global Cell & Gene Therapy Cold Chain Logistics Market growth in the forecast period.

 

According to TechSci Research report, “Cell & Gene Therapy Cold Chain Logistics Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2019-2029F”, the Global Cell & Gene Therapy Cold Chain Logistics Market stood at USD 1680.76 Million in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 14.11% through 2029. The Global Cell & Gene Therapy Cold Chain Logistics Market is undergoing dynamic growth, driven by several key factors reshaping healthcare delivery worldwide. As cell and gene therapies emerge as groundbreaking treatments for various diseases such as cancer, genetic disorders, and autoimmune conditions, the demand for advanced cold chain logistics solutions is rising. These therapies, often tailored to individual patients, require precise temperature-controlled environments to preserve their efficacy and safety throughout the supply chain. This necessitates the deployment of sophisticated cold chain logistics infrastructure capable of safeguarding sensitive biological materials from manufacturing facilities to patient administration sites.

The market is witnessing significant innovation and investment in technologies and services tailored to meet the unique requirements of cell and gene therapy logistics. Cryogenic shippers, ultra-low temperature storage freezers, and specialized packaging solutions are among the critical components enhancing the efficiency and reliability of cold chain logistics operations. The integration of cold chain management systems, IoT-enabled sensors, and real-time tracking devices enables stakeholders to proactively monitor and manage temperature-sensitive shipments, ensuring compliance with regulatory standards and mitigating risks of product loss or damage.

The globalization of the cell and gene therapy market is reshaping supply chain dynamics, driving the expansion of cold chain logistics networks across international borders. As therapies receive regulatory approvals in multiple countries, logistics providers must navigate diverse regulatory frameworks, cultural nuances, and logistical challenges to ensure seamless global distribution. Strategic partnerships, collaborations, and alliances between pharmaceutical companies, logistics providers, and research institutions are fostering knowledge sharing, capacity building, and innovation in cold chain logistics, further fueling market growth.

Despite promising growth prospects, the Global Cell & Gene Therapy Cold Chain Logistics Market faces several challenges and complexities. Strict regulatory compliance requirements, supply chain fragmentation, cost pressures, and the need for continuous technological advancements are among the key challenges confronting stakeholders in the industry. However, with proactive measures such as robust quality assurance processes, standardized protocols, and investment in innovation, stakeholders can overcome these challenges and capitalize on the vast opportunities presented by the burgeoning cell and gene therapy market.

The Global Cell & Gene Therapy Cold Chain Logistics Market is poised for continued expansion and evolution as it plays a crucial role in facilitating the safe and timely delivery of life-changing therapies to patients worldwide. As advancements in biotechnology and healthcare delivery accelerate, cold chain logistics will remain at the forefront of innovation, ensuring that patients receive the transformative treatments they need to enhance their quality of life and well-being.

                                                                                              

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Cell & Gene Therapy Cold Chain Logistics Market

The Global Cell & Gene Therapy Cold Chain Logistics Market is segmented into component, services offered, mode of transportation, holding temperature range, end user, regional distribution, and company

Based on mode of transportation, the air transportation emerged as the dominant segment in the global cell & gene therapy cold chain logistics market in 2023. Several factors contribute to air transportation's prominence in this sector. Air transportation offers unparalleled speed and efficiency, enabling the rapid and timely delivery of temperature-sensitive biologics, including cell and gene therapies, to patients worldwide. With the ability to cover vast distances in a matter of hours, air transportation facilitates the expedited movement of these life-saving treatments from manufacturing facilities to distribution centers, clinical sites, and ultimately to patients in need. Air transportation provides a high level of reliability and predictability, crucial factors in ensuring the integrity and efficacy of temperature-sensitive products throughout the supply chain. Airlines and air cargo carriers invest heavily in state-of-the-art cold chain infrastructure and technologies, including temperature-controlled storage facilities, specialized packaging solutions, and real-time monitoring systems, to maintain optimal conditions for the transportation of biologics. These advancements enable precise temperature control, minimize temperature excursions, and ensure compliance with regulatory requirements, thereby safeguarding the quality and safety of cell and gene therapies during transit.

Based on region, Europe emerged as the second largest region in the Global Cell & Gene Therapy Cold Chain Logistics Market in 2023. Europe's prominence in this sector is underpinned by several key factors contributing to its robust growth and innovation. Europe boasts a thriving biotechnology and pharmaceutical industry, with a strong focus on research and development in cell and gene therapy. Leading pharmaceutical companies, academic institutions, and research organizations in countries such as the United Kingdom, Germany, France, and Switzerland are at the forefront of advancing cutting-edge therapies for a wide range of diseases.  Europe has a sophisticated infrastructure and logistics network, comprising modern transportation hubs, state-of-the-art storage facilities, and well-established cold chain logistics providers. These infrastructure investments enable seamless distribution of temperature-sensitive biologics across the region and beyond, supporting clinical trials, commercialization efforts, and patient access to advanced therapies. Europe's extensive network of healthcare institutions and clinical research centers provides a robust foundation for conducting cell and gene therapy trials and delivering innovative treatments to patients.

 

Major companies operating in Global Cell & Gene Therapy Cold Chain Logistics Market are:

  • Cencora, Inc.
  • United Parcel Service, Inc.
  • Catalent, Inc.
  • BioLife Solutions, Inc.
  • Cryoport System, LLC
  • Atelerix Ltd.
  • Life Science Group Ltd (LSG)
  • Yourway Biopharma Services Company
  • Bertelsmann SE & Co. KGaA  
  • NMDP BioTherapies


Download Free Sample Report

Customers can also request for 10% free customization on this report

 

“The future of the Cell & Gene Therapy Cold Chain Logistics Market is poised for continued growth and innovation as advancements in biotechnology and healthcare delivery reshape the treatment landscape. With an increasing focus on personalized medicine and the commercialization of novel cell and gene therapies, the demand for specialized cold chain logistics solutions will soar. Key trends driving market evolution include the adoption of advanced technologies such as IoT-enabled sensors and real-time tracking systems, expansion of global logistics networks to support international distribution, and strategic collaborations between stakeholders to streamline supply chain operations. Regulatory harmonization, sustainability initiatives, and ongoing investments in infrastructure will further enhance the efficiency, reliability, and sustainability of cold chain logistics for cell and gene therapies, ensuring safe and timely delivery to patients worldwide,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

 

Cell & Gene Therapy Cold Chain Logistics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Component (Cryogenic Shippers, Cryogenic Storage Freezers, Ultra Low Freezers, Cold Chain Management Systems, Shipment and Storage Medium, Cryogenic Packout Kits, Others), By Services Offered (Transportation, Storage, Packaging) By Mode of Transportation (Air, Ground, Water), By Holding Temperature Range (Cryogenic, Refrigerated, Ambient, Others), By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others), By Region and Competition, 2019-2029F”, has evaluated the future growth potential of Global Cell & Gene Therapy Cold Chain Logistics Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Cell & Gene Therapy Cold Chain Logistics Market.

 

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com

Relevant News